3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
6
Depression
6
Breast Neoplasms
6
Multiple Myeloma
5
Leukemia
4
Brain Neoplasms
4
Waldenstrom Macroglobulinemia
3
Sezary Syndrome
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Burkitt Lymphoma
3
Vomiting
2
Nausea
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Interventions
burosumab
2
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Nevus, Sebaceous of Jadassohn
×
Therapeutics
×
Clear all
NCT04320316
2022-10-07
ENS
University of Alabama at Birmingham
Phase 4
Completed
1 enrolled
10 charts